{
    "clinical_study": {
        "@rank": "83997", 
        "arm_group": [
            {
                "arm_group_label": "bilateral repetitive transcranial magnetic stimulation", 
                "arm_group_type": "Active Comparator", 
                "description": "Bilateral protocol:\nMotor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
            }, 
            {
                "arm_group_label": "unilateral repetitive transcranial magnetic stimulation", 
                "arm_group_type": "Active Comparator", 
                "description": "Unilateral protocol:\nMotor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to investigate the effect of repetitive TMS in reduction of\n      depressive symptoms in patients with bipolar disorder. In a randomized, single blind\n      clinical trials, 30 patients with bipolar disorder in Atieh Neuroscience center will be\n      assigned to receive bilateral TMS and unilateral TMS, daily; for 20 sessions. The depressive\n      and anxiety symptoms and quality of life will be assessed before the treatment (pre test)\n      during the treatment (10th session), and after the treatment (post test). QEEG apply before\n      and after rTMS in all subjects."
        }, 
        "brief_title": "The Study of Effectiveness Repetitive Transcranial Magnetic Stimulation in Bipolar Depression", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Bipolar Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Outpatients male and female with the range of 18-65 years of age\n\n          2. The diagnosis of Bipolar disorder according to DSM-IV-TR\n\n          3. Completion of consent form\n\n          4. Being under supervision of a psychiatrist,\n\n          5. Having BDI>14\n\n          6. Being able to adhere to treatment schedule,\n\n          7. Having stable symptoms as defined by not requiring a change in medication for at\n             least 4 weeks .\n\n        Exclusion Criteria:\n\n          1. The history of rTMS treatment for any reason\n\n          2. Intracranial implant and other ferromagnetic materials close to the head\n\n          3. Cardiac pacemaker\n\n          4. Drug pumps\n\n          5. The risk of seizure with any reasons\n\n          6. High intracranial pressure\n\n          7. The history of epilepsy or seizure in the first relatives\n\n          8. Any metal in head\n\n          9. Pregnancy\n\n         10. Breastfeeding\n\n         11. High risk of suicide 12 Having personality disorder in axis II"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932749", 
            "org_study_id": "143"
        }, 
        "intervention": {
            "arm_group_label": [
                "bilateral repetitive transcranial magnetic stimulation", 
                "unilateral repetitive transcranial magnetic stimulation"
            ], 
            "intervention_name": "Transcranial Magnetic stimulation", 
            "intervention_type": "Device", 
            "other_name": "Magstim rapid 2"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "1969713663"
                }, 
                "name": "Atieh neuroscience center"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Comparison of Effectiveness of Bilateral rTMS Versus Unilateral TMS in Patients With Bipolar Depression: a Study Randomized and Single Blind", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The BDI-II is measured depressive symptoms is administered before treatment, session 10, immediately after treatment.", 
            "measure": "Change in depression severity.Depression will be assessed using the Beck depression inventory", 
            "safety_issue": "No", 
            "time_frame": "Baseline to four weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932749"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Neuroscience Center, LLC", 
            "investigator_full_name": "reza kazemi", 
            "investigator_title": "Researcher", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The BAI is measured for anxiety and is administered before treatment, session 10, immediately after treatment.", 
                "measure": "Change in anxiety severity .Anxiety will be assessed using the Beck Anxiety inventory.", 
                "safety_issue": "No", 
                "time_frame": "Test Day 1, 10 & 20"
            }, 
            {
                "description": "The WHOQOL-BREF is administered for measuring of quality of life before treatment, session 10, immediately after treatment", 
                "measure": "Change in World Health Organization Quality of Life- BREF (WHOQOL-BREF)", 
                "safety_issue": "No", 
                "time_frame": "Test Day 1, 10& 20"
            }, 
            {
                "description": "QEEG and LORETA is applying for assessment brain waves patterns", 
                "measure": "Change in QEEG and low resolution brain electromagnetic tomography (LORETA)", 
                "safety_issue": "No", 
                "time_frame": "Before treatment, immediately after treatment"
            }
        ], 
        "source": "University of Tehran", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Tehran", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}